Production (Stage)
Apellis Pharmaceuticals, Inc.
APLS
$17.44
-$0.34-1.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -92.23M | -36.35M | -57.45M | -37.66M | -66.42M |
| Total Depreciation and Amortization | 446.00K | 447.00K | 457.00K | 449.00K | 444.00K |
| Total Amortization of Deferred Charges | 591.00K | 587.00K | 658.00K | 238.00K | 76.00K |
| Total Other Non-Cash Items | 27.37M | 26.31M | 27.48M | 34.81M | 36.42M |
| Change in Net Operating Assets | 10.40M | 28.37M | 62.95M | -6.18M | -103.50M |
| Cash from Operations | -53.41M | 19.36M | 34.10M | -8.34M | -132.98M |
| Capital Expenditure | -8.00K | -20.00K | 0.00 | -90.00K | -293.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -8.00K | -20.00K | 0.00 | -90.00K | -293.00K |
| Total Debt Issued | -- | 0.00 | 0.00 | 365.45M | -- |
| Total Debt Repaid | -- | -- | 1.59M | -1.59M | -- |
| Issuance of Common Stock | 281.00K | 1.64M | 2.56M | 5.16M | 9.48M |
| Repurchase of Common Stock | -7.00K | -15.00K | -14.00K | 0.00 | -28.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -5.63M | -1.59M | -326.53M | 98.76M |
| Cash from Financing | 274.00K | -4.00M | 2.54M | 42.49M | 108.21M |
| Foreign Exchange rate Adjustments | 359.00K | -965.00K | 173.00K | 342.00K | -209.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -52.79M | 14.38M | 36.81M | 34.40M | -25.27M |